论文部分内容阅读
目的:探讨分析对支原体感染盆腔炎患者使用阿奇霉素联合盆腔炎2号方进行治疗的临床价值。方法:选取医院于2013年2月到2015年3月所收治的支原体感染盆腔炎的患者84例,随机分两组,每组42例,对照组患者仅使用阿奇霉素治疗,实验组患者则在阿奇霉素治疗的基础上,使用盆腔炎2号方进行治疗,比较分析两组治疗效果。结果:对照组患者治疗总有效率为88.0%,不良反应发生率为:35.7%,实验组患者治疗总有效率为:97.6%,不良反应发生率19.0%,两组差异均具有统计学意义(p<0.05)。结论:对支原体感染盆腔炎患者,使用阿奇霉素联合盆腔炎2号方进行治疗,能够获得良好的治疗效果,降低不良反应与并发症发生的几率,加速患者康复速度,值得推广应用。
Objective: To investigate the clinical value of using azithromycin in combination with pelvic inflammatory disease in patients with mycoplasma-induced pelvic inflammatory disease. Methods: Eighty-four patients with mycoplasmal infection of pelvic inflammatory disease from February 2013 to March 2015 in our hospital were randomly divided into two groups (n = 42 in each group). Patients in the control group were treated with azithromycin only, while patients in the experimental group were treated with azithromycin On the basis of treatment, the use of pelvic inflammatory disease on the 2nd side treatment, comparative analysis of two groups of treatment. Results: The total effective rate of the control group was 88.0%, the incidence of adverse reactions was 35.7%, the total effective rate of the experimental group was 97.6%, the incidence of adverse reactions was 19.0%, the difference between the two groups was statistically significant ( p <0.05). Conclusion: Mycoplasma infection in patients with pelvic inflammatory disease, the use of azithromycin combined with pelvic inflammatory disease on the 2nd party to be able to get a good therapeutic effect, reduce the incidence of adverse reactions and complications, accelerate the recovery rate of patients, it is worth promoting the application.